Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Tzung-Dau Wang, Ru-San Tan, Hae-Young Lee...
https://pubmed.ncbi.nlm.nih.gov/27849566/Actively Recruiting
Led by Martin Rohacek · Updated on 2026-07-02
298
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effect of switching from angiotensin converting enzyme ACE inhibitors or angiotensin receptor blockers ARB to angiotensin-neprilysin inhibitors ARNI in adults with symptomatic heart failure with reduced ejection fraction HFrEF in rural Tanzania. Heart failure is a significant health issue in sub-Saharan Africa, with high mortality rates, and this study aims to assess the health status benefits and safety of sacubitrilvalsartan ARNI in this population where it has not been previously studied except in South Africa. Participants who have been on stable heart failure treatment with ACE inhibitors or ARBs, beta-blockers, and spironolactone for at least 3 months will switch to sacubitrilvalsartan after a 36-hour washout of ACE inhibitors. The dose will start at 50 mg twice daily for two weeks, increase to 100 mg twice daily for three weeks, and then to 200 mg twice daily. Beta blockers and spironolactone will continue, with diuretics adjusted as needed. The study period includes 10 months of follow-up with scheduled visits for assessments and medication adherence. During the study, participants will undergo baseline and follow-up evaluations including physical exams, questionnaires measuring health status Kansas City Cardiomyopathy Questionnaire, 6-minute walking tests, echocardiography, blood tests for biomarkers like brain natriuretic peptide BNP, and monitoring of vital signs. Medication adherence will be tracked by pill count and self-report. Safety and efficacy outcomes, including quality of life improvements, heart function, and hospitalization rates, will be measured over 10 months. Sacubitrilvalsartan will be provided free during the study, and transport costs for visits will be reimbursed.
CONDITIONS
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
M
Martin Rohacek, PD Dr med
S
Samuel S Mutasingwa, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Martin Rohacek
Lead Sponsor
Ifakara Health Institute (IHI)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 10 months
Participants switch from ACE inhibitors or ARBs to sacubitril/valsartan with gradually increasing doses while continuing other heart failure medications. Regular follow-up visits include health assessments and medication adherence checks.
Visits at 2 weeks, 5 weeks, 2, 4, 6, and 10 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Tzung-Dau Wang, Ru-San Tan, Hae-Young Lee...
https://pubmed.ncbi.nlm.nih.gov/27849566/Merrill Thomas, Yevgeniy Khariton, Gregg C Fonarow...
https://pubmed.ncbi.nlm.nih.gov/33932120/Eric J Velazquez, David A Morrow, Adam D DeVore...
https://pubmed.ncbi.nlm.nih.gov/30415601/Hisham Dokainish, Koon Teo, Jun Zhu...
https://pubmed.ncbi.nlm.nih.gov/28476564/Michele Senni, John J V McMurray, Rolf Wachter...
https://pubmed.ncbi.nlm.nih.gov/27170530/Nasrien E Ibrahim, Ileana L Piña, Alexander Camacho...
https://pubmed.ncbi.nlm.nih.gov/33016100/Pilly Chillo, Jackson Mlay, Precious W Akanyirige...
https://pubmed.ncbi.nlm.nih.gov/37149565/Alexandre Mebazaa, Beth Davison, Ovidiu Chioncel...
https://pubmed.ncbi.nlm.nih.gov/36356631/C P Green, C B Porter, D R Bresnahan...
https://pubmed.ncbi.nlm.nih.gov/10758967/John J V McMurray, Milton Packer, Akshay S Desai...
https://pubmed.ncbi.nlm.nih.gov/25176015/Martin Rohacek
Lead Sponsor
Ifakara Health Institute (IHI)
Collaborating Sponsor